SG
BSX icon

Sankala Group’s Boston Scientific BSX Stock Holding History

Sankala Group’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5K Hold
166
– – 0.01% 364
2025
Q4 		$12.8K Buy
+166
New +$16.3K 0.01% 357

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sankala Group's BSX Position: Q1 2026 in Review

Sankala Group held its Boston Scientific (BSX) position steady in Q1 2026 at 166 shares worth $11.5K. The position accounts for 0.01% of the portfolio, ranked #364.

Sankala Group first reported a position in BSX in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.8K in Q4 2025. 1,672 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Sankala Group held 166 shares of Boston Scientific worth $11.5K as of Q1 2026.
  • Sankala Group left its Boston Scientific share count unchanged in Q1 2026.
  • Boston Scientific made up 0.01% of Sankala Group's portfolio in Q1 2026, its #364 holding.
  • Sankala Group first reported a position in Boston Scientific in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Boston Scientific position peaked at $12.8K in Q4 2025.
  • 1,672 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.